Repligen

Repligen

Yahoo Finance • 8 days ago

Repligen Corporation (RGEN) Surges on Revenue Beat and Raised Full-Year Organic Outlook

Conestoga Capital Advisors, an asset management company, released its third-quarter 2026 investor letter. The letter can be downloaded here. In 2026, Small Caps initially outperformed but faced challenges in the third quarter, marked by th... Full story

Yahoo Finance • 9 days ago

Repligen (RGEN) Stock Looks Fairly Valued As Cash Flow Growth Is Priced In

Repligen has delivered a 57.8% gain over the past three years, which puts real weight on the question of whether today's share price lines up with the cash the business is expected to generate over time. With the stock now around US$180.17... Full story

Yahoo Finance • 27 days ago

These healthcare stocks have the highest EPS revision grade ahead of Q3 results

[Health Care Medical Stock Market Industry Sector Wall Street Buildings 3d Illustration] iQoncept/iStock via Getty Images As Q3 2026 earnings season approaches, healthcare stocks are drawing investor attention as markets assess earnings e... Full story

Yahoo Finance • last month

Freshworks Set to Join S&P SmallCap 600

NEW YORK, Oct. 5, 2026 /PRNewswire/ -- Freshworks Inc. (NASD: FRSH) will replace BioLife Solutions Inc. (NASD:BLFS) in the S&P SmallCap 600 effective prior to the open of trading on Thursday, October 8. S&P MidCap 400 constituent Repligen... Full story

Yahoo Finance • last month

Freshworks stock climbs on S&P SmallCap 600 inclusion

Investing.com -- Freshworks Inc (NASDAQ:FRSH) shares rose 4% in after-hours trading Monday following the announcement that the company will join the S&P SmallCap 600 index. Before you buy NVIDIA: our AI model's stock picks are beating the... Full story

Yahoo Finance • last month

3 Healthcare Stocks That Concern Us

3 Healthcare Stocks That Concern Us Healthcare companies are pushing the status quo by innovating in areas like drug development and digital health. Shareholders who bet on the industry have been rewarded lately as healthcare stocks have... Full story

Yahoo Finance • last month

3 Unpopular Stocks Walking a Fine Line

3 Unpopular Stocks Walking a Fine Line Wall Street's bearish price targets for the stocks in this article signal serious concerns. Such forecasts are uncommon in an industry where maintaining cordial corporate relationships often trumps d... Full story

Yahoo Finance • last month

Alkermes Posts Positive Data From Phase I ADHD Study on ALKS 7290

Alkermes ALKS announced positive top-line data from a phase I proof-of-concept study evaluating its novel, investigational orexin 2 receptor (OX2R) agonist, ALKS 7290, for the treatment of attention-deficit hyperactivity disorder (ADHD).... Full story

Yahoo Finance • last month

JNJ's Caplyta Shows Benefit in Bipolar 1 Related Mania Study

Johnson & Johnson JNJ announced positive top-line data from a pivotal phase III study evaluating Caplyta (lumateperone) for treating manic episodes, with or without mixed features, in adults with bipolar I disorder. More on JNJ's Latest S... Full story

Yahoo Finance • last month

NVS Gets Positive CHMP Opinion for Cosentyx for Another Indication

Novartis NVS announced that the Committee for Medicinal Products for Human Use ("CHMP") of the European Medicines Agency ("EMA") has issued a positive opinion recommending marketing authorization for an additional indication of its arthrit... Full story

Yahoo Finance • last month

Merck Gets CHMP Backing for Keytruda-Padcev Combo in Bladder Cancer

Merck MRK announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use ("CHMP") has issued a positive opinion recommending approval of a combination of its blockbuster PD-L1 inhibitor, Keytruda (pembr... Full story

Yahoo Finance • last month

CHMP Backs CORT's Lifyorli Combo in Platinum-Resistant Ovarian Cancer

Corcept Therapeutics CORT announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion recommending approval of Lifyorli (relacorilant) in combination with nab-pac... Full story

Yahoo Finance • 2 months ago

Roche Gets FDA Priority Tag for Enspryng in Rare Autoimmune Disorder

Roche RHHBY announced that the FDA has accepted its supplemental biologics license application (sBLA) seeking approval of Enspryng (satralizumab) for the treatment of myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD).... Full story

Yahoo Finance • 2 months ago

Novartis' Del-desiran Fails Late-Stage DM1 Study, Shares Fall

Novartis AG NVS announced that the late-stage HARBOR study evaluating del-desiran in people living with myotonic dystrophy type 1 (DM1) failed to meet the primary endpoint. Del-desiran is an investigational antibody oligonucleotide conjug... Full story

Yahoo Finance • 2 months ago

ABBV's Etentamig Meets Goals in Phase III Multiple Myeloma Study

AbbVie ABBV reported positive top-line data from the phase III CERVINO study, evaluating its investigational pipeline candidate, etentamig, in certain patients with relapsed/refractory multiple myeloma (RRMM) who had received prior treatme... Full story

Yahoo Finance • 2 months ago

Novartis' Remibrutinib Delivers Positive Results in Late-Stage MS Studies

Novartis NVS announced positive top-line results from the late-stage REMODEL-1/-2 studies on remibrutinib in relapsing multiple sclerosis (RMS). Remibrutinib is a highly selective oral Bruton's tyrosine kinase (BTK) inhibitor that blocks... Full story

Yahoo Finance • 2 months ago

GSK to Advance mRNA Influenza Vaccine Into Phase III Development

GSK plc GSK announced that it plans to advance the mRNA-based seasonal influenza (flu) vaccine candidate into late-stage development. This advancement is supported by positive results from a phase II study, which showed that the company's... Full story

Yahoo Finance • 2 months ago

Axsome Begins Phase III Study on AXS-05 for Smoking Cessation

Axsome Therapeutics AXSM announced that it has dosed the first patient in the phase III SUMMIT study evaluating AXS-05 for the treatment of smoking cessation. The randomized, double-blind, placebo-controlled phase III SUMMIT study is desi... Full story

Yahoo Finance • 2 months ago

JAZZ Rises on Updated OS Results From Gastric Cancer Study

Jazz Pharmaceuticals JAZZ announced second interim top-line overall survival (OS) results from the phase III HERIZON-GEA-01 study, which evaluated different combination regimens involving its marketed drug, Ziihera (zanidatamab) as a first... Full story

Yahoo Finance • 2 months ago

1 Profitable Stock on Our Buy List and 2 We Brush Off

1 Profitable Stock on Our Buy List and 2 We Brush Off Even if a company is profitable, it doesn't always mean it's a great investment. Some struggle to maintain growth, face looming threats, or fail to reinvest wisely, limiting their futu... Full story